TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7747540

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin 5 mg/kg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical dithranol and ultraviolet B therapy
Number of subjects: 60
Study: 1443489

Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia machine feedback signaling only successful demands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient controlled analgesia machine feedback acknowledging every demand
Number of subjects: 0
Study: 3083829

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 X 150 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol (4 X 50 micrograms/d and 4 X 200 micrograms/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil (3 X 100 micrograms/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole (5 mg and 10 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 X 25 mg/d)
Number of subjects: 0
Study: 30413972

Group type: EXPERIMENTAL
Intervention: Community Water Fluoridation (CWF)
Number of subjects: 474
Study: 30261031

Group type: EXPERIMENTAL
Intervention: Specialized palliative care intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not receiving specialized palliative care intervention)
Number of subjects: 18
Study: 27531110

Group type: EXPERIMENTAL
Intervention: CSCLR (coaxially sighted corneal light reflex)
Number of subjects: 420

Group type: COMPARATOR
Intervention: LOS (line of sight)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CSCLR
Number of subjects: 420

Group type: COMPARATOR
Intervention: LOS
Number of subjects: 420
Study: 25135997

Group type: EXPERIMENTAL
Intervention: Rituximab treatment with vitamin D levels ≤ 8 ng/mL
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Rituximab treatment with vitamin D levels > 8 ng/mL
Number of subjects: 422

Group type: COMPARATOR
Intervention: Rituximab treatment without vitamin D deficiency (levels ≤ 8 ng/mL or > 8 ng/mL)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Vitamin D substitution in individuals with VDD
Number of subjects: 422
Study: 22751518

Group type: EXPERIMENTAL
Intervention: Operative performance ratings (OPRs) by blinded expert judges
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Supervising surgeon ratings
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interrater agreement among expert judges
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Use of local and national norms for interpretation of OPRs
Number of subjects: 8
Study: 20478056

Group type: EXPERIMENTAL
Intervention: CHEST PAIN CHOICE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 0
Study: 19045974

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Community Treatment by Experts (CTBE)
Number of subjects: 101
Study: 15924587

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) co-administered with atorvastatin (ATV)
Number of subjects: 450
Study: 12803814

Group type: EXPERIMENTAL
Intervention: Erroneous verbalizations by an accomplice
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adequate thoughts verbalized by an accomplice
Number of subjects: 32

Group type: COMPARATOR
Intervention: No verbalizations by an accomplice
Number of subjects: 32
Study: 9702082

Group type: EXPERIMENTAL
Intervention: Reverse transcriptase polymerase chain reaction (RT-PCR)
Number of subjects: 20
Study: 7956631

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 102
Study: 3291601

Group type: EXPERIMENTAL
Intervention: Guar gum added to the usual diet four times per day for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo added to the usual diet four times per day for 4 weeks
Number of subjects: 9
Study: 31168711

Group type: EXPERIMENTAL
Intervention: Eight sessions of moderate intensity aerobic exercise along with eight self-management modules during chemotherapy.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 29683702

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE) alone
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE) + alcohol use disorder treatment
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE) + nicotine use disorder treatment
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Combined model analysis
Number of subjects: 216
Study: 28642081

Group type: COMPARATOR
Intervention: Intravenous THC administered during the Rey‐Auditory Verbal Learning Test (RAVLT) in experiment #2 (n=57).
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo administered before the Rey‐Auditory Verbal Learning Test (RAVLT) in experiment #1 (n=38).
Number of subjects: 95
Study: 26189203

Group type: EXPERIMENTAL
Intervention: Cognitive impairment (subjective and objective measures)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Subjective cognitive impairment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Objective cognitive impairment (slower processing speed and poorer inhibitory control)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Subjective and objective measures of cognitive impairment
Number of subjects: 121
Study: 24136693

Group type: EXPERIMENTAL
Intervention: Addition of obesity to the problem list
Number of subjects: 497

Group type: COMPARATOR
Intervention: No addition of obesity to the problem list (Control)
Number of subjects: 497
Study: 21936683

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard GP care
Number of subjects: 61
Study: 18573713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16263773

Group type: EXPERIMENTAL
Intervention: 480 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 24 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased amino acid load
Number of subjects: 0
Study: 12694671

Group type: COMPARATOR
Intervention: Clinical staging (arm A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Surgical staging (arm B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach (LAP)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach (EXP)
Number of subjects: 61
Study: 10636142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 857
Study: 9100037

Group type: EXPERIMENTAL
Intervention: Calcium supplementation with protein- and phosphorous-restricted diet
Number of subjects: 157

Group type: COMPARATOR
Intervention: Phosphorous-load diet
Number of subjects: 157

Group type: COMPARATOR
Intervention: Protein- and phosphorous-restricted diet without calcium supplementation
Number of subjects: 157
Study: 8299406

Group type: EXPERIMENTAL
Intervention: EDTA treatment (20 repeated infusions of 3 grams over 5-9 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 3106234

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (250 mg/kg body weight, intravenous route, days 3 to 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no Pseudomonas immunoglobulin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin
Number of subjects: 26
Study: 29392727

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 27267753

Group type: EXPERIMENTAL
Intervention: MEDI-551 (0.1-10.0 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24633684

Group type: EXPERIMENTAL
Intervention: Standard hygiene intervention (S)
Number of subjects: 30209

Group type: EXPERIMENTAL
Intervention: Enhanced standard hygiene intervention (ES)
Number of subjects: 30209

Group type: EXPERIMENTAL
Intervention: Chlorhexidine body wash (CHG)
Number of subjects: 30209
Study: 23901089

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Control (uncircumcised men)
Number of subjects: 2784
Study: 19837551

Group type: EXPERIMENTAL
Intervention: Core decompression and implantation of a biomaterial-loaded allograft threaded cage
Number of subjects: 76

Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 76
Study: 19024525

Group type: EXPERIMENTAL
Intervention: Domestic docetaxel (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Taxotere (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Number of subjects: 88
Study: 16487524

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12538218

Group type: EXPERIMENTAL
Intervention: Upper lip bite test
Number of subjects: 300

Group type: COMPARATOR
Intervention: Modified Mallampati test
Number of subjects: 300
Study: 10547170

Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated interventions
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated interventions involving anti-infective agents
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Control group (observed patients)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Overall cost-saving interventions
Number of subjects: 1226
Study: 8975568

Group type: EXPERIMENTAL
Intervention: Combined use of opiate premedication, regional blocking, and parenteral diclophenak-Na before and after the operation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control groups (one or several components excluded from the protocol of anesthesia)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Preventive analgesia
Number of subjects: 152
Study: 1809047

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study: 7196167

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 48

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 48

Group type: COMPARATOR
Intervention: enflurane
Number of subjects: 48
Study: 31689890

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (225 ug/day, potassium iodide tablets)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29331170

Group type: EXPERIMENTAL
Intervention: Enhanced terminal disinfection with UV disinfection devices
Number of subjects: 18411

Group type: EXPERIMENTAL
Intervention: Strategies to overcome barriers to implementation
Number of subjects: 18411
Study: 26385269

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 2709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2709
Study: 25146513

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg once daily
Number of subjects: 436

Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg twice daily
Number of subjects: 436
Study: 21481225

Group type: EXPERIMENTAL
Intervention: Whole rye kernel bread
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Milled rye kernel bread
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rye kernel breakfast
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sifted wheat bread (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Milled rye kernel porridge
Number of subjects: 44
Study: 18279549

Group type: COMPARATOR
Intervention: Diet C (increased consumption of cereals)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 60
Study: 16511902

Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive screening result
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative screening result or declined screening
Number of subjects: 0
Study: 12693793

Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (160/4.5 microg, two inhalations)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (160/4.5 microg, one inhalation)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Budesonide (400 microg) once-daily
Number of subjects: 523
Study: 10711617

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution rinsed twice during 4 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution rinsed three times during 24 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline rinsed control
Number of subjects: 8
Study: 8617089

Group type: EXPERIMENTAL
Intervention: Selective digestion decontamination (SDD) using amphotericin B, colistin sulfate, and gentamicin applied every 6 hours
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 148
Study: 1399729

Group type: EXPERIMENTAL
Intervention: Protocol 7506 (black patients)
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Protocols 7706 and 8307 (black patients)
Number of subjects: 1294
Study: 3903382

Group type: EXPERIMENTAL
Intervention: Flatoril (dimethicone 200 mg and clebopride 0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30616012

Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 5997

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5997
Study: 27918968

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy with asynchronous therapeutic support
Number of subjects: 205
Study: 26122037

Group type: EXPERIMENTAL
Intervention: Group A: 500μW/cm2 of unfiltered LED light
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group B: 1500μW/cm2 LED light with blue-blocking glasses (achieving 500μW/cm2 at eye level)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups after light exposure
Number of subjects: 20
Study: 23492647

Group type: EXPERIMENTAL
Intervention: ARB+D (losartan 50mg + hydrochlorothiazide 12.5mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: ARB+C (amlodipine 5mg + typical dosage of ARBs)
Number of subjects: 140
Study: 21486810

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 18690015

Group type: EXPERIMENTAL
Intervention: mpHBV (modified process hepatitis B vaccine)
Number of subjects: 860

Group type: COMPARATOR
Intervention: RECOMBIVAX HB (control vaccine)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: mpHBV and RECOMBIVAX HB (control vaccine)
Number of subjects: 860
Study: 16957573

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/day for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment change)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 22
Study: 12515990

Group type: EXPERIMENTAL
Intervention: Homecare hospice intervention
Number of subjects: 150
Study: 11097593

Group type: EXPERIMENTAL
Intervention: Topical proparacaine hydrochloride 0.5%
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Exposure to oleoresin capsicum (pepper spray)
Number of subjects: 47
Study: 9024449

Group type: EXPERIMENTAL
Intervention: CRP-guided treatment (group 1)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: CRP-guided treatment (group 2a)
Number of subjects: 176

Group type: COMPARATOR
Intervention: At least 5-day treatment (group 2b)
Number of subjects: 176
Study: 1332213

Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously once daily (200 U(anti‐FXa)/kg/24h)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously twice daily (100 U(anti‐FXa)/kg/12h)
Number of subjects: 101
Study: 2948442

Group type: EXPERIMENTAL
Intervention: CMF + HD-MPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 100
Study: 31765871

Group type: EXPERIMENTAL
Intervention: Teaching for Creativity Module (TCM) intervention, which included a 2-day workshop followed by 6 hours of reinforcement in the classroom over an 18-week capstone course.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 42
Study: 29471226

Group type: EXPERIMENTAL
Intervention: Exposure to patient testimonials about Medical Cannabis (MC)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Exposure to narratives with external attribution of disease responsibility
Number of subjects: 396

Group type: COMPARATOR
Intervention: Non-narrative video containing equivalent information about MC
Number of subjects: 396
Study: 26934538

Group type: EXPERIMENTAL
Intervention: Web‐based multiple computer tailoring and counseling by a practice nurse (MTC)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Computer tailoring without counseling (MT)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 414
Study: 24864592

Group type: COMPARATOR
Intervention: Ondansetron 4mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg with Dexamethasone 8mg
Number of subjects: 100
Study: 22169794

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily and Sorafenib 400 mg twice daily (MTD)
Number of subjects: 15
Study: 20589888

Group type: EXPERIMENTAL
Intervention: Motor Unit Number Index (MUNIX) measurements
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study: 18684771

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 500 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 375 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 250 microg
Number of subjects: 120
Study: 17313008

Group type: EXPERIMENTAL
Intervention: Shu‐Mu point combination
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine needling
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine (Danazol)
Number of subjects: 90
Study: 12927310

Group type: EXPERIMENTAL
Intervention: Phytoestrogen rich diet
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 10721508

Group type: EXPERIMENTAL
Intervention: Manual physical therapy combined with supervised exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 52
Study: 8936356

Group type: EXPERIMENTAL
Intervention: ORG 2766 0.1 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ORG 2766 0.4 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ORG 2766 2 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 1339125

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide‐baking soda dentifrice
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 83
Study: 6388715

Group type: EXPERIMENTAL
Intervention: Ornithine-8-vasopressin injection
Number of subjects: 113
Study: 31276540

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 76
Study: 30341115

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 25370439

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Number of subjects: 77
Study: 22177939

Group type: EXPERIMENTAL
Intervention: Educational sessions for asthma patients (60 minutes duration)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Educational sessions for COPD patients (60 minutes duration)
Number of subjects: 25
Study: 20488250

Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual exercise therapy (UC; usual care)
Number of subjects: 149
Study: 18797484

Group type: EXPERIMENTAL
Intervention: UKPDS risk engine
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: NZGG-modified Framingham equation
Number of subjects: 423

Group type: COMPARATOR
Intervention: Original Framingham equation
Number of subjects: 423

Group type: COMPARATOR
Intervention: Combined UKPDS coronary heart disease plus stroke equations
Number of subjects: 423
Study: 16013350

Group type: EXPERIMENTAL
Intervention: New balloon catheters
Number of subjects: 238

Group type: COMPARATOR
Intervention: 1 time reused balloon catheters
Number of subjects: 238

Group type: COMPARATOR
Intervention: 2 times reused balloon catheters
Number of subjects: 238

Group type: COMPARATOR
Intervention: 3 times reused balloon catheters
Number of subjects: 238

Group type: COMPARATOR
Intervention: Reused balloon catheters
Number of subjects: 238
Study: 12776579

Group type: EXPERIMENTAL
Intervention: DHEP formulation with lecithin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Marketed DHEP formulation without lecithin
Number of subjects: 12
Study: 9873241

Group type: EXPERIMENTAL
Intervention: Infants with atopic dermatitis (AD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy infants (control group)
Number of subjects: 40
Study: 7731275

Group type: EXPERIMENTAL
Intervention: Financial and office systems intervention including full Medicare reimbursement for preventive care, regular prompting of physicians, new office system with nurses carrying out preventive procedures.
Number of subjects: 1914

Group type: COMPARATOR
Intervention: Usual-care control group.
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Financial and office systems intervention.
Number of subjects: 1914
Study: 1673937

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1.0 g
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both metronidazole and placebo groups combined
Number of subjects: 100